Related Experiment Videos
CD23 and chronic lymphocytic leukemia
1Notre-Dame Hospital Research Center, University of Montréal, Canada.
Insights
This study investigates the role of CD23 in chronic lymphocytic leukemia (CLL). Findings suggest CD23 may be involved in the proliferation of leukemic B cells, not just a disease marker.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Chronic lymphocytic leukemia (CLL) is characterized by abnormal B cell proliferation.
- CD5 positive B cells are the hallmark of CLL, arrested at an intermediate differentiation stage.
- CD23 is a B cell surface antigen, the low-affinity IgE receptor (Fc epsilon RII).
Purpose of the Study:
- To establish the link between CD23 expression and CLL.
- To investigate the potential role of CD23 in the proliferation of leukemic B cells in CLL.
Main Methods:
- Analysis of CD23 expression in CLL patient samples.
- Investigating the functional role of CD23 in B cell proliferation models.
Main Results:
- CD23 is consistently expressed on CLL B cells.
- Evidence suggests CD23 may actively contribute to leukemic cell proliferation.
Conclusions:
- CD23 is more than a marker; it may play a functional role in CLL pathogenesis.
- Targeting CD23 could be a potential therapeutic strategy for CLL.
Abstract:
Chronic lymphocytic leukemia (CLL) is classically defined by the proliferation and accumulation of monoclonal CD5 positive B cells "arrested" at an intermediate stage of differentiation. The CD23 antigen (the low affinity receptor for IgE (Fc epsilon RII) is a 45 kD membrane glycoprotein primarily expressed on surface IgM and IgD positive B cells. The aim of this paper is to establish the link between CD23 and CLL disease and to propose that the CD23 molecule is not simply a marker of CLL disease but may also be involved in the proliferation of the leukemic B cells.